Tags : Clinical Development

Biotech

Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous

Shots: Janssen has initiated P-Ib proof-of-concept clinical trial assessing Guselkumab vs PBO in 72 patients with familial adenomatous polyposis (FAP). With the initiation of P-Ib study for FAP, MorphoSys will receive milestones from Janssen Earlier, Janssen collaborated with MorphoSys to develop Guselkumab utilizing MorphoSys’s HuCAL antibody technology (Human Combinatorial Antibody Library), a platform for invitro […]Read More

Pharma

Novartis & Pfizer Enter into a Clinical Development Collaboration to

Shots: The agreement involves a clinical trial assessing Novartis’s tropifexor and Pfizer’s compounds, including PF-05221304, PF-06865571 & PF-06835919 for treatment of NASH Novartis’ tropifexor (LJN452) is a Farnesoid X receptor (FXR) agonist indicated for NASH and has also received FTD by the US FDA for NASH with liver fibrosis in Oct, 2016 PF-05221304, PF-06865571 & […]Read More